FY2030 Earnings Estimate for TSE:ONC Issued By HC Wainwright

Oncolytics Biotech Inc. (TSE:ONC) – Research analysts at HC Wainwright decreased their FY2030 earnings per share (EPS) estimates for shares of Oncolytics Biotech in a research report issued on Tuesday, May 26th. HC Wainwright analyst P. Trucchio now forecasts that the company will earn $0.19 per share for the year, down from their prior forecast of $0.25. The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.41) per share.

Oncolytics Biotech Trading Down 1.3%

Shares of Oncolytics Biotech stock opened at C$14.90 on Wednesday. The business’s fifty day moving average is C$14.90 and its two-hundred day moving average is C$14.90. The company has a quick ratio of 8.86, a current ratio of 2.88 and a debt-to-equity ratio of 14.58. Oncolytics Biotech has a fifty-two week low of C$0.44 and a fifty-two week high of C$2.08. The firm has a market cap of C$1.50 billion, a PE ratio of -40.27 and a beta of 0.80.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc to co-develop pelareorep, as well as with Roche Holding AG.